G Atropine0.6mg/ml

• Sinus bradycardia (ACLS)
• Asystole / Pulseless Electrical Activity (ACLS)
• Organophosphorus poisoning
• Anesthesia premedication (antisialagogue)
• Bronchospasm (nebulization)
• Cycloplegia and mydriasis for eye examination
• Uveitis treatment
• Myopia progression control in children (0.01% solution)

Injection (IV/IM/SC):

• Anesthesia premedication: 0.4-0.6 mg, 30-60 min before anesthesia; repeat q4-6hr PRN
• Sinus bradycardia (ACLS): 0.5-1 mg or 0.04 mg/kg IV q5min; max 3 mg
• Asystole/PEA (ACLS): 1 mg IV q3-5min; up to 0.04 mg/kg
• Organophosphorus poisoning: 2 mg IV/IM, q10-30min until muscarinic effects resolve; maintain atropinization for at least 2 days
• Bronchospasm (nebulization): 0.025 mg/kg (max 2.5 mg/dose) in 2.5 mL NS, q6-8hr

Eye Drops (0.01% & 1%):

• Uveitis (1%): 1 drop three times daily
• Refraction (1%): 1 drop twice daily for 1-2 days before exam, and 1 hour before exam
• Myopia control (0.01%): 1 drop at night in each eye; continue for at least 2 years

Common (Eye Drops):

• Blurred vision
• Photophobia
• Local irritation
• Follicular conjunctivitis
• Vascular congestion, edema, exudate
• Contact dermatitis, eczematous dermatitis

Common (Injection/Systemic):

• Dry mouth
• Dysphagia
• Constipation
• Flushing and dry skin
• Tachycardia, palpitations, arrhythmias
• Mydriasis, photophobia, cycloplegia
• Raised intraocular pressure

Toxic doses: Tachycardia, hyperpyrexia, restlessness, confusion, excitement, hallucinations, delirium, circulatory failure, respiratory depression.

Serious Precautions:

• Contraindicated in angle-closure glaucoma [citation:4]
• Total dose should not exceed 0.03-0.04 mg/kg in patients with coronary artery disease [citation:9]
• May cause viscid plugs in chronic lung disease
• May cause complete urinary retention in prostatic hypertrophy
• May convert partial pyloric stenosis to complete obstruction
• Extreme caution in Down's syndrome, spastic paralysis, or brain damage [citation:4]
• Caution in pregnancy and lactation